Critical Limb Ischemia (CLI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

• Publication date: August 2011

Critical Limb Ischemia (CLI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Critical Limb Ischemia (CLI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Critical Limb Ischemia Therapeutics market. The report identifies the key tre...

Critical Limb Ischemia (CLI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Critical Limb Ischemia (CLI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Critical Limb Ischemia Therapeutics market. The report identifies the key trends shaping and driving the global Critical Limb Ischemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Critical Limb Ischemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Critical Limb Ischemia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Critical Limb Ischemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Critical Limb Ischemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Critical Limb Ischemia Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Critical Limb Ischemia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Critical Limb Ischemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Critical Limb Ischemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Critical Limb Ischemia Therapeutics market landscape? – Identify, understand and capitalize.

Therapy Industry in the United Kingdom

1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Critical Limb Ischemia Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Risk Factors 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.6 Pathophysiology 11
2.7 Treatment and Management Options 12
2.7.1 Revascularization 13
2.7.2 Surgical Procedures 13
2.7.3 Pharmacological treatment 13
2.7.4 Amputation 14
2.8 GlobalData Pipeline Report Guidance 14
3 Critical Limb Ischemia Therapeutics: Market Characterization 15
3.1 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – Global 15
3.2 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – Global 16
3.3 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – The US 17
3.4 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – The US 18
3.5 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – France 19
3.6 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – France 20
3.7 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – Germany 21
3.8 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – Germany 22
3.9 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – Italy 23
3.10 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – Italy 24
3.11 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – Spain 25
3.12 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – Spain 26
3.13 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – The UK 27
3.14 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – The UK 28
3.15 Critical Limb Ischemia Therapeutics Market Size (2005-2010) – Japan 29
3.16 Critical Limb Ischemia Therapeutics Market Forecast (2010-2017) – Japan 30
3.17 Drivers and Barriers for the Critical Limb Ischemia Therapeutics Market 31
3.17.1 Drivers for the Critical Limb Ischemia Therapeutics Market 31
3.17.2 Barriers for the Critical Limb Ischemia Therapeutics Market 31
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 33
4 Critical Limb Ischemia Therapeutics - Competitive Assessment 34
4.1 Overview 34
4.1.1 Strategic Competitor Assessment 34
4.2 Product Profiles for the Major Marketed Products in the Critical Limb Ischemia Therapeutics Market 35
4.2.1 Antiplatelets 35
4.2.2 Lipid Lowering Agents 36
4.2.3 Beta Blockers 37
4.2.4 Others 38
4.3 Key Takeaway 38
5 Critical Limb Ischemia Therapeutics - Pipeline Assessment 39
5.1 Overview 39
5.2 Strategic Pipeline Assessment 39
5.3 Critical Limb Ischemia Therapeutics Pipeline – Pipeline by Phases of Development 39
5.3.1 Critical Limb Ischemia Therapeutics – Phase III Products 39
5.3.2 Critical Limb Ischemia Therapeutics – Phase II Pipeline 40
5.3.3 Critical Limb Ischemia Therapeutics – Phase I Pipeline 40
5.3.4 Critical Limb Ischemia Market – Pre-Clinical Pipeline 40
5.3.5 Technology Trends Analytic Framework 41
5.4 Critical Limb Ischemia Therapeutics Market – Clinical Pipeline by Mechanism of Action 42
5.5 Critical Limb Ischemia Therapeutics – Promising Drugs Under Clinical Development 43
5.6 Molecule Profile for Promising Drugs Under Clinical Development 43
5.6.1 Collategene 43
5.6.2 Ixmyelocel-T (Vascular Repair Cells) 44
5.7 NV1FGF Failure - Recent Disappointment for a CLI Gene Therapy 45
5.7.1 Overview 45
5.7.2 Efficacy 45
5.7.3 Safety 45
5.7.4 Clinical Study Details 45
5.8 Key Takeaway 46
6 Critical Limb Ischemia Therapeutics - Clinical Trials Mapping 47
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 47
6.2 Clinical Trials by Phase 48
6.3 Clinical Trials by Trial Status 49
6.4 Prominent Sponsors 50
6.5 Top Companies Participating in Critical Limb Ischemia Therapeutics Clinical Trials 52
7 Critical Limb Ischemia Therapeutics - Strategic Assessment 53
7.1 Key Events Impacting the Future Market 53
7.2 Critical Limb Ischemia Therapeutics: Implications for Future Market Competition 53
8 Critical Limb Ischemia Therapeutics - Future Players 55
8.1 Introduction 55
8.2 Company Profiles 55
8.2.1 AnGesMG, Inc. 55
8.2.2 Aastrom Biosciences 57
8.2.3 Other Companies in the Critical Limb Ischemia Therapeutics Market 59
9 Licensing and Partnership Deals 60
10 Critical Limb Ischemia Therapeutics: Appendix 61
10.1 Market Definitions 61
10.2 Abbreviations 61
10.3 Research Methodology 62
10.3.1 Coverage 62
10.3.2 Secondary Research 63
10.3.3 Forecasting 63
10.3.4 Primary Research 65
10.3.5 Expert Panel Validation 66
10.4 Contact Us 66
10.5 Disclaimer 66
10.6 Bibliography 66

1.1 List of Tables

Table 1: Critical Limb Ischemia Therapeutics Market, Global, Revenue ($m), 2005–2010 15
Table 2: Critical Limb Ischemia Therapeutics Market, Global, Forecast ($m), 2010–2017 16
Table 3: Critical Limb Ischemia Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Table 4: Critical Limb Ischemia Therapeutics Market, The US, Forecasts ($m), 2010–2017 18
Table 5: Critical Limb Ischemia Therapeutics Market, France, Revenue ($m), 2005–2010 19
Table 6: Critical Limb Ischemia Therapeutics Market, France, Forecasts ($m), 2010–2017 20
Table 7: Critical Limb Ischemia Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Table 8: Critical Limb Ischemia Therapeutics Market, Germany, Forecasts ($m), 2010–2017 22
Table 9: Critical Limb Ischemia Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Table 10: Critical Limb Ischemia Therapeutics Market, Italy, Forecasts ($m), 2010–2017 24
Table 11: Critical Limb Ischemia Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Table 12: Critical Limb Ischemia Therapeutics Market, Spain, Forecasts ($m), 2010–2017 26
Table 13: Critical Limb Ischemia Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Table 14: Critical Limb Ischemia Therapeutics Market, The UK, Forecasts ($m), 2010–2017 28
Table 15: Critical Limb Ischemia Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Table 16: Critical Limb Ischemia Therapeutics Market, Japan, Forecasts ($m), 2010–2017 30
Table 17: Critical Limb Ischemia Therapeutics – Phase III Pipeline, 2011 39
Table 18: Critical Limb Ischemia Therapeutics – Phase II Pipeline, 2011 40
Table 19: Critical Limb Ischemia Therapeutics – Phase I Pipeline, 2011 40
Table 20: Critical Limb Ischemia Therapeutics – Pre-clinical Pipeline, 2011 40
Table 21: Critical Limb Ischemia Therapeutics – Most Promising Drugs Under Clinical Development, 2011 43
Table 22: Critical Limb Ischemia Therapeutics – Clinical Trials by Country, 2011 47
Table 23: Critical Limb Ischemia Therapeutics – Clinical Trials by Phase, 2011 48
Table 24: Critical Limb Ischemia Therapeutics – Clinical Trials by Status, 2011 49
Table 25: Critical Limb Ischemia Therapeutics – Prominent Sponsors, 2011 51
Table 26: Critical Limb Ischemia Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 52
Table 27: AnGesMG, Inc. – Cardiovascular Diseases, Pipeline, 2011 56
Table 28: AnGesMG, Inc. Deals, Alliances and Partnerships, 2011 57
Table 29: Aastrom Biosciences – Cardiovascular Diseases, Pipeline, 2011 58
Table 30: Aastrom Biosciences Deals, Alliances and Partnerships, 2011 58
Table 31: Critical Limb Ischemia Therapeutics Market – Future Players 59
Table 32: Critical Limb Ischemia Therapeutics, Global, Deals, 2011 60

1.2 List of Figures

Figure 1: Types of Critical Limb Ischemia 7
Figure 2: Critical Limb Ischemia 8
Figure 3: Leriche Fontaine Classification 9
Figure 4: Diagnosis of Critical Limb Ishemia 10
Figure 5: CLI Therapeutics - Treatment of Critical Limb Ischemia 12
Figure 6: Critical Limb Ischemia Therapeutics Market, Global, Revenue ($m), 2005–2010 15
Figure 7: Critical Limb Ischemia Therapeutics Market, Global, Forecast ($m), 2010–2017 16
Figure 8: Critical Limb Ischemia Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Figure 9: Critical Limb Ischemia Therapeutics Market, The US, Forecast ($m), 2010–2017 18
Figure 10: Critical Limb Ischemia Therapeutics Market, France, Revenue ($m), 2005–2010 19
Figure 11: Critical Limb Ischemia Therapeutics Market, France, Forecast ($m), 2010–2017 20
Figure 12: Critical Limb Ischemia Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Figure 13: Critical Limb Ischemia Therapeutics Market, Germany, Forecast ($m), 2010–2017 22
Figure 14: Critical Limb Ischemia Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Figure 15: Critical Limb Ischemia Therapeutics Market, Italy, Forecast ($m), 2010–2017 24
Figure 16: Critical Limb Ischemia Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Figure 17: Critical Limb Ischemia Therapeutics Market, Spain, Forecast ($m), 2010–2017 26
Figure 18: Critical Limb Ischemia Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Figure 19: Critical Limb Ischemia Therapeutics Market, The UK, Forecast ($m), 2010–2017 28
Figure 20: Critical Limb Ischemia Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Figure 21: Critical Limb Ischemia Therapeutics Market, Japan, Forecast ($m), 2010–2017 30
Figure 22: Opportunity and Unmet Need in the Critical Limb Ischemia Therapeutics Market 32
Figure 23: Critical Limb Ischemia Therapeutics – Strategic Competitor Assessment, 2010 34
Figure 24: Critical Limb Ischemia Therapeutics – Pipeline by Phase of Development, 2011 39
Figure 25: Critical Limb Ischemia Therapeutics – Technology Trends Analytics Framework, 2011 41
Figure 26: Critical Limb Ischemia Therapeutics – Technology Trends Analytics Framework – Description, 2011 41
Figure 27: Critical Limb Ischemia Therapeutics – Pipeline by Mechanism of Action, 2011 42
Figure 28: Critical Limb Ischemia Therapeutics – Clinical Trials by Country, 2011 47
Figure 29: Critical Limb Ischemia Therapeutics – Clinical Trials by Phase, 2011 48
Figure 30: Critical Limb Ischemia Therapeutics – Clinical Trials by Status, 2011 49
Figure 31: Critical Limb Ischemia Therapeutics – Overall Sponsors, 2011 50
Figure 32: Critical Limb Ischemia Therapeutics – Prominent Sponsors, 2011 51
Figure 33: Critical Limb Ischemia Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 52
Figure 34: Critical Limb Ischemia Therapeutics Market, Drivers and Restraints, 2011 53
Figure 35: Implications for Future Market Competition in the Critical Limb Ischemia Market, 2011 53
Figure 36: Critical Limb Ischemia Therapeutics Market – Pipeline by Company, 2011 55
Figure 37: GlobalData Market Forecasting Model 65

Companies Mentioned
AnGesMG, Inc.
Aastrom Biosciences